An exosome-related gene signature predicts prognosis, immune suppression, and therapeutic sensitivity in luminal breast cancer

Key Points

• The research aims to identify gene markers linked to immune suppression and treatment response in luminal breast cancer.
• Identified LCN2, RRAS2, LRG1, and LTF as prognostic markers.
• Analyzed their relationship with immune suppression and tumor progression.
• Evaluated sensitivity to PI3K inhibitors and chemotherapy drugs among high-risk groups.
• LCN2, RRAS2, LRG1, and LTF serve as effective prognostic markers for luminal breast cancer.
• High-risk cases demonstrated heightened sensitivity to PI3K inhibitors and chemotherapy.
• Markers are associated with immune suppression and tumor progression.